Budget Impact Analysis of the Incorporation of Ibrutinib for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia in the Brazilian Private Health Care System

May 1, 2016, 00:00 AM
10.1016/j.jval.2016.03.1551
https://www.valueinhealthjournal.com/article/S1098-3015(16)01619-3/fulltext
Section Title : Cancer - Cost Studies
Section Order : 268
First Page : A143
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01619-3&doi=10.1016/j.jval.2016.03.1551
HEOR Topics :
Tags :
Regions :